Lilly and Novo Nordisk GLP-1 contest may hinge on cost and prescriber habits
An analysis finds that what patients pay and which drug their clinician prefers may decide the GLP-1 market, with 55% of insured users saying cost was hard.
An analysis published Aug. 21, 2026 argues that the contest between Eli Lilly and Novo Nordisk over GLP-1 market share will be settled less by how much weight each product takes off than by what patients pay and which drug their clinician reaches for first [1]. The BioPharma Dive review draws on surveys covering affordability, prescribing and public attitudes [1].
Money is the loudest signal in that evidence. KFF polling cited in the review found that 55% of people who currently use or previously used a GLP-1 and have health insurance described affording the prescription as difficult [1]. Injectables generally run $25 to $150 a month when a plan covers them, though many plans decline to pay when the only reason for use is weight loss [1]. Paying cash changes the picture sharply: $900 to $1,400 a month on average, for medicines usually taken long term [1].
Pills cost less, at least at the advertised cash rate. Both Novo's oral Wegovy (semaglutide) and Lilly's Foundayo (orforglipron) start near $149 a month for people without insurance, and insured patients can face co-pays as low as $25 [1]. Cheaper compounded copies draw some patients, but they carry safety concerns, and plenty of people simply quit [1]. Prescribers surveyed by Spherix Global Insights put the share of patients who stopped treatment because of cost at 74% [1].
The same Spherix poll, which drew on 185 doctors, nurse practitioners and physician assistants, showed satisfaction gaps. Eighty percent said they were highly satisfied with Zepbound (tirzepatide); the figure was 59% for Wegovy, 48% for the Wegovy pill and 47% for Foundayo [1]. Zepbound came out on top for amount, speed and durability of weight loss as well as tolerability, while ranking poorly on what patients pay out of pocket [1]. Wegovy took the lead on cardiovascular evidence and access; its pill form scored best on affordability [1].
Commercial results are mixed for both manufacturers. Lilly's second-quarter revenue approached $23 billion, a 48% increase from a year earlier, which the company credited to Mounjaro and Zepbound; an Evaluate report estimates the two tirzepatide products will be worth $70 billion by 2032 [1]. Foundayo brought in $98 million in the quarter and missed analyst forecasts, growing more slowly since its April launch than Novo's Wegovy pill [1]. Novo's oral Wegovy nearly doubled analyst expectations with $354 million in first-quarter sales yet still landed under projections for April through June; the company says it has passed 5 million prescriptions since January and has raised its earnings outlook [1].
Reputation matters too. A HarrisX–Allison Worldwide survey of more than 6,000 adults in the U.S. and U.K. found that almost one in four U.S. adults said they had used a GLP-1, and 23% more said they would consider it [1]. Half of respondents called the drugs a shortcut to weight loss, and close to three-quarters of U.S. participants said too many people take them to change their appearance [1]. Support was still broad: 66% considered GLP-1 use socially acceptable, and 64% said they would be open about taking one [1].
Why it matters for patients
If the analysis is right, the practical differences between these drugs will show up in formularies, prior authorization rules, co-pays and cash prices as much as in trial results [1]. A product that prescribers rate most highly can still be the one they consider hardest to pay for, as happened with Zepbound in the Spherix poll, and the cheapest pill is not the one with the strongest heart data [1]. Nothing in the surveys says what a given plan will cover; coverage terms vary by plan and have not been described in detail.
What happens next
No dates are attached to the two policy and research threads the analysis mentions. TrumpRx, a federal website, directs patients to discounted GLP-1 drugs [1]. Separately, ongoing research into long-term health benefits could open the door to wider insurance coverage, according to IQVIA [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.